McEldrew Young's 2012 qui tam lawsuit against Salix and the resulting government investigation revealed a company lavishing prescribers with thousands of dollars in speaking fees, expensive dinners, drinks, and entertainment in order to increase the number of prescriptions written by doctors for Xifaxan, Apriso, Relistor, MoviPrep, OsmoPrep, Solesta and Deflux. From January 2009 through December 2013, Salix employees throughout the United States held "speaker" programs that were primarily social in nature. The complained of misconduct included, for example: " Salix decided to resolve the government's investigation into its sham speaker program payments after being confronted with a mountain of evidence provided, in large part, by our clients," said James J. McEldrew, III, a Partner at McEldrew Young, and Past President of the Philadelphia Trial Lawyers Association.